LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
| 5.44 | |
| 5.38 | |
| - | |
| 5.45 | |
| 5.0844 | |
| 1.8-5.5999 | |
| 61 202 K | |
| 11 397 K | |
| 44 500 K | |
| -0.19 | |
| 0.649 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Upgrades For Emergent BioSolutions Inc (NYSE:EBS), Chardan Capital upgraded the previous rating of Neutral to Buy. Emergent BioSolutions earned $3.67 in the fourth quarter, compared to $1.57 in the y...
INCLINE VILLAGE, Nev., Oct. 2, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has completed the previously announced spin-off of its femtoseco...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
